Ajanta Pharma is currently trading at Rs. 1963.00, up by 2.65 points or 0.14% from its previous closing of Rs. 1960.35 on the BSE.
The scrip opened at Rs. 1960.05 and has touched a high and low of Rs. 1963.00 and Rs. 1959.00 respectively.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2150.00 on 28-Oct-2016 and a 52 week low of Rs. 1103.00 on 18-Jan-2016.
Last one week high and low of the scrip stood at Rs. 2150.00 and Rs. 1937.75 respectively. The current market cap of the company is Rs. 17,337.00 crore.
The promoters holding in the company stood at 73.78%, while Institutions and Non-Institutions held 12.48% and 13.74% respectively.
Ajanta Pharma has received USFDA approval for launch of Amlodipine + Olmesartan Medoxomil Tablets in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc. It is a bioequivalent generic version of Azor tablets, used for lowering blood pressure and company has launched the product in 4 strengths, 5mg+20mg, 5mg+40mg, 10mg+20mg, 10mg+40mg tablets.
Amlodipine + Olmesartan Medoxomil Tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 29 Abbreviated New Drug Application (ANDA) of which it has for 16 final ANDA approvals; 2 tentative approvals; and 11 ANDAs under review with USFDA.
Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. The company is engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.
